key: cord-0800649-d0k3ez8j authors: Zinovkin, R. A.; Grebenchikov, O. A. title: Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients date: 2020-07-13 journal: Biochemistry (Mosc) DOI: 10.1134/s0006297920070111 sha: f2dde841d404142fc2d5dcac6f8efa43b05ecd77 doc_id: 800649 cord_uid: d0k3ez8j Nrf2 is a key transcription factor responsible for antioxidant defense in many tissues and cells, including alveolar epithelium, endothelium, and macrophages. Furthermore, Nrf2 functions as a transcriptional repressor that inhibits expression of the inflammatory cytokines in macrophages. Critically ill patients with COVID-19 infection often present signs of high oxidative stress and systemic inflammation – the leading causes of mortality. This article suggests rationale for the use of Nrf2 inducers to prevent development of an excessive inflammatory response in COVID-19 patients. Pathogenesis of COVID 19 infection is a subject of active research. However, no effective therapy has yet been developed for this disease caused by the SARS CoV 2 coronavirus. Initially, SARS CoV 2 infects upper respiratory tract epithelial cells. If the infection is limited to these cells, the disease usually manifests mild symp toms. Severe pneumonia can develop when the virus enters alveoli of the lungs and infects type II pneumo cytes. The infection inhibits interferon response while upregulates expression of chemokines attracting immune cells (monocytes, B and T lymphocytes) [1] . Excessive extravasation of these cells from the vessels into the alve oli is considered the main cause of pathogenic changes in the lungs, leading to the development of respiratory fail ure and acute respiratory distress syndrome (ARDS) [2] . In severe cases of COVID 19 infection, the virus can enter bloodstream and infect endothelial and other target cells in kidneys, esophagus, bladder, ileum, heart tissues, and central nervous system. The endogenous "damage associated molecular patterns, DAMPs" released from the dead cells additionally activate immune cells and sup port development of the cytokine storm. Thus, in severe forms of COVID 19 infection multiple organ failure asso ciated with hyperactivation of the immune system is observed. Patients with COVID 19 infection in critical condition often have high systemic inflammatory param eters, including levels of C reactive protein and cytokines IL 6, TNFα, IL 8, etc. [3 5] . Increased generation of reactive oxygen species (ROS) by immune cells and oxidative stress [6] inevitably accompanies the cytokine storm. Inflammatory cytokines and ROS act together, activating pulmonary epithelial and endothelial cells. This leads to disassembly of cell contacts, increased permeability, and influx of edematous fluid into alveoli resulting in an impaired gas exchange in the lungs. In addition, cytokine storm and oxidative stress lead to ROS dependent apoptosis of endothelial cells [7] , which contributes to the release of coagulation factors and clot formation [8] . Corticosteroids and inflammatory cascade inhibitors based on monoclonal antibodies are currently used for the treatment of the cytokine storm in COVID 19 infec tion: tocilizumab (anti IL 6), secukinumab (anti IL 17A), canakinumab (anti IL 1β), ruksolitinib phosphate BIOCHEMISTRY (Moscow) Vol. 85 No. 7 2020 (JAK kinase inhibitor), etc. [4] . Use of corticosteroids for treatment of COVID 19 infection showed noticeable constraints related primarily to the suppression of specif ic immunity and an increased risk of secondary bacterial pneumonia [9, 10] . Limitations of the monoclonal anti body therapy include their narrowly targeted action at only one of the many inflammatory cytokines. Thus, it is extremely important to develop new approaches to pre vent cytokine storm during the COVID 19 infection. The transcription factor Nrf2 (Nuclear factor ery throid 2 related factor 2) is responsible for adaptation of cells under electrophilic or oxidative stresses. Under nor mal condition, Nrf2 is located in the cytoplasm bound to its inhibitor Keap1, which targets Nrf2 for ubiquitination and subsequent degradation. In the presence of elec trophiles or ROS, the Keap1 Nrf2 complex dissociates and Nrf2 migrates to the nucleus, where it stimulates transcription of the target genes with antioxidant response element sequences in their promoters [11] . Nrf2 controls expression of the genes participating in antioxi dant response, redox homeostasis, biogenesis of mito chondria, etc. Activation of these genes protects cells from inflammation [12] . Nrf2 stimulates expression of hemoxygenase (HO 1), which is responsible for degrada tion of the pro inflammatory free heme and formation of the anti inflammatory compounds -CO and bilirubin. Nrf2 also upregulates production of the antioxidant enzyme NAD(P)H: quinone oxidoreductase (NQO1), as well as of the key enzymes of glutathione biosynthesis, which functions as the main cellular antioxidant. Nrf2 knockout mice suffer from an uncontrolled inflammatory reaction involving activation of innate immune cells, increased production of cytokines, chemokines, and ROS. All these factors contribute to cell and tissue dam age [13] . Nrf2 activation results in suppression of inflamma tion not only through the antioxidant response, but also through the Nrf2 transcriptional repressor activity. In human macrophages, Nrf2 inhibits expression of the inflammatory cytokines IL 1β, IL 6, and TNFα [14] . It was shown in numerous animal inflammatory models that Nrf2 inducers decreased circulating levels of proinflam matory cytokines [12, 15 17] . Protective role of the Nrf2 activation in numerous inflammatory processes was also demonstrated for airway epithelium and vascular endothelium [18 22 ]. Dozens of clinical trials are cur rently underway to test the efficacy of Nrf2 inducers for prevention and treatment of inflammatory and respirato ry diseases. The main facts and observations justifying feasibility of the Nrf2 activation in treatment of COVID 19 infec tion are summarized below: 1. Excessive inflammation in COVID 19 infection is associated with high lethality [3] . Activation of Nrf2 reduces inflammatory response preventing expression of the inflammatory cytokines [14] and activation of the macrophage inflammasomes [23, 24] . Nrf2 inducers also reduce inflammatory reactions in patients with acute and chronic diseases [25] . 2. ARDS is the main mortality factor in COVID 19 patients [26] . Activation of Nrf2 protects airway epitheli um from disassembly of the intracellular tight junctions during inflammatory exposure and subsequent develop ment of ARDS [27] . 3. An impaired vascular permeability is a key event in the COVID 19 pathogenesis leading to endothelial dys function and thrombosis [28] . Induction of Nrf2 protects vascular endothelium from damage caused by the oxida tive stress or inflammatory cytokines [29] . 4. Severe cases of COVID 19 are accompanied by an increased oxidative stress [30] . There are some cases of successful treatment of COVID 19 with glutathione [31] . Key enzymes of glutathione biosynthesis are controlled by Nrf2 [32] . The decrease of Nrf2 activity promotes oxidative stress, and Nrf2 activation increases glutathione content in the body and restores redox balance in the organism [33] . 5. Age is an important risk factor for severe COVID 19 infection [34] . Nrf2 activity decreases with age [33] . 6. Hyperglycemia is another risk factor in COVID 19 infection [34] . Nrf2 activity is reduced in patients with hyperglycemia [35] . 7. Mortality and severity of COVID 19 infection is higher in men compared to women [34] . Sexual differ ences in Nrf2 activity in humans are unknown, but female mice have higher Nrf2 activity compared to males [36] . So far, no attempts have been made to investigate Nrf2 inducers as the therapeutic drugs that reduce oxida tive stress and inflammation in infections caused by SARS CoV 2. This task can be solved by repurposing of the drugs or drug candidates that are able to activate Nrf2 response. A wide range of compounds can be used to acti vate Nrf2, including the following: 1. Sulforaphane is a plant derived compound found in cruciferous plants such as broccoli and Brussels sprouts. The effect of sulforaphane on reducing circulato ry inflammatory cytokines has been demonstrated in many animal models [37] . Currently, about 70 clinical tri als with sulforaphane are conducted targeting chronic obstructive pulmonary disease, asthma, arthritis, cancer, and others. Sulforaphane is well tolerated orally in daily doses up to 200 μmol, reaching therapeutic plasma con centrations [38] . 2. Dimethyl fumarate is a dimethyl ester of fumaric acid. In the USA it has been approved by the FDA for treatment of recurrent multiple sclerosis (trade name Tecfidera), and in Germany for psoriasis (trade name Fumaderm). Interestingly, dimethyl fumarate reduces BIOCHEMISTRY (Moscow) Vol. 85 No. 7 2020 inflammatory reactions in both Nrf2 dependent [39] and Nrf2 independent ways [40, 41] . 3. Sodium thiosulfate is a drug used intravenously and orally. It is a safe substance used to treat various intoxications. Sodium thiosulfate is a hydrogen sulfide (H 2 S) donor, which is a Nrf2 inducer. Hydrogen sulfide maintains redox balance of the cells and has an anti inflammatory property [42] . The compounds releasing H 2 S have anti inflammatory and antiviral activities against a wide range of pathogenic viruses [43] . A review paper has recently been published justifying the use of inhaled form of sodium thiosulphate for patients with COVID 19 infection [44] . 4 . Epigallocatechin 3 gallate is a polyphenol found in green tea. This non toxic compound displays an anti inflammatory activity both in vitro and in vivo [45] . In addition, epigallocatechin 3 gallate is an inhibitor of furin -a protease that processes SARS CoV 2 S protein and facilitates virus penetration into the cell [ 46 48 ]. 5. Resveratrol is a plant polyphenol. Resveratrol acti vates Nrf2 by decreasing the expression of its negative regulator KEAP1 and activates SIRT1 deacetylase [49] . Oral administration of resveratrol leads to the decrease in the levels of inflammatory cytokines (IL 1β and TNF) and activation of the expression of Nrf2 target genes (NQO1 and glutathione S transferase) [50] . Resveratrol enhances synthesis of endogenous glutathione and pro tects alveolar epithelial cells from oxidative stress [51] . These drugs are mainly used to treat chronic rather than acute inflammatory conditions. Therapeutic effica cy of these Nrf2 inducers is unknown for the cytokine storm and ARDS. Potentially, Nrf2 inducers can be used to prevent cytokine storm or during its manifestation in combination with already used anti inflammatory drugs. For most of the proposed drugs toxicity and bioavail ability are already known, which allows for a quick start of the relevant clinical trials. To reduce oxidative stress and inflammation in COVID 19 infection, it seems reason able to use Nrf2 inducers together with glutathione biosynthesis precursors, e.g., N acetylcysteine. This ther apy can be used to reduce damage to cells and tissues, to prevent respiratory failure, and ARDS. Funding. This work received no financial support. Imbalanced host response to SARS CoV 2 drives development of COVID 19 Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid 19 Across Speciality Collaboration (2020) COVID 19: consider cytokine storm syndromes and immunosuppression The use of anti inflammatory drugs in the treat ment of people with severe coronavirus disease 2019 (COVID 19): the perspectives of clinical immunologists from China Clinical and immunological features of severe and moderate coronavirus disease ROS function in redox signaling and oxidative stress The role of endothe lial cell apoptosis in inflammatory and immune diseases Incidence of thrombotic complications in critically ill ICU patients with COVID 19 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneu monia in Wuhan, China: a descriptive study Corticosteroid treatment of patients with coron avirus disease 2019 (COVID 19) Nrf2 Keap1 defines a physiologically important stress response mecha nism Nrf2 signaling pathway: pivotal roles in inflammation Cell survival responses to environmental stresses via the Keap1 Nrf2 ARE pathway Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription Nrf2 dependent pro tection from LPS induced inflammatory response and mor tality by CDDO imidazolide Sulforaphane suppressed LPS induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway HYCO 3, a dual CO releaser/Nrf2 activator, reduces tissue inflammation in mice challenged with lipopolysaccharide Nrf2 protects human alveolar epithelial cells against injury induced by influenza A virus Nrf2 is essential for pro tection against acute pulmonary injury in mice NRF2 targeting: a promising ther apeutic strategy in chronic obstructive pulmonary disease Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proin flammatory state Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expres sion The role of Nrf2 in NLRP3 inflammasome activation Nuclear factor E2 related factor 2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation Activators and inhibitors of NRF2: a review of their potential for clinical development Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease Ethyl gallate attenuates acute lung injury through Nrf2 sig naling Is COVID 19 an endothelial disease? Clinical and basic evidence Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging Highlights of COVID 19 patho genesis. Insights into oxidative damage Efficacy of glutathione therapy in relieving dyspnea associ ated with COVID 19 pneumonia: a report of 2 cases Nrf2 is a key transcrip tion factor that regulates antioxidant defense in macrophages and epithelial cells: protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals Oxidative stress response and Nrf2 signaling in aging, Free Radic and the Northwell COVID 19 Research Consortium (2020) Presenting char acteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID 19 in the New York City area The Keap1 Nrf2 system pre vents onset of diabetes mellitus Activation of Nrf2 in the liver is associated with stress resistance mediated by suppression of the growth hor mone regulated STAT5b transcription factor The transcription factor Nrf2 is a therapeutic target against brain inflammation Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi The anti inflammatory effects of dimethyl fumarate in astro cytes involve glutathione and haem oxygenase 1 Dimethyl fumarate treatment induces adaptive and innate immune modulation inde pendent of Nrf2 Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immuni ty Role of hydrogen sulfide in NRF2 and sirtuin dependent main tenance of cellular redox balance Broad range antiviral activity of hydrogen sulfide against highly pathogenic RNA viruses Possible applica tion of H2S producing compounds in therapy of coron avirus (COVID 19) infection and pneumonia Anti inflammatory action of green tea Polyphenols can inhibit furin in vitro as a result of the reac tivity of their auto oxidation products to proteins Cell entry mechanisms of SARS CoV 2 The spike glycopro tein of the new coronavirus 2019 nCoV contains a furin like cleavage site absent in CoV of the same clade Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2 A resveratrol and polyphenol prepara tion suppresses oxidative and inflammatory stress response to a high fat, high carbohydrate meal Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke mediated oxidative stress in human lung epithelial cells Acknowledgements. The authors are grateful to A. S. Prikhodko for critical discussions.Ethics declarations. The authors declare no conflict of interest in financial or any other sphere. This article does not contain any studies with human participants or animals performed by any of the authors.